Physical health monitoring of patients with schizophrenia.

By S. R. Marder, S. Essock, Alexander L. Miller, Robert W. Buchanan, Daniel E. Casey, John M Davis, John M. Kane, J. Lieberman, Nina R. Schooler, Nancy H. Covell and 12 more. American Journal of Psychiatry, 2004

848 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cardiology and Cardiovascular Medicine, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/43a10ba9b3c15927c72f6169ceda3c269e3b0cdc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Psychiatry and Mental health

Citations in the corpus

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level (2011, background): “Two consensus conferences have called on mental health care providers to take responsibility for the physical health of their patients (7,8).”
Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. (2007, background): “The lack of association between atypical antipsychotics and CHD death, however, is counterintuitive given the interest in metabolic effects of such agents.(1) Channeling bias cannot be discounted, whereby people most at risk of cardiovascular disease such as those who are older or overweight may be ”
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? (2007, background): “A systematic approach to monitoring and treating the physical health needs of people with schizophrenia is clearly warranted.(98) Several important caveats to this review should be noted.”
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “Antipsychotics with a high affi nity for binding to D2-receptors are more likely to induce hyperprolactinemia, while the precise mechanisms of SGAs on pituitary dopamine D2-receptors have not been fully clarifi ed (Marder et al. 2004; Turrone”
Inequalities in healthcare provision for people with severe mental illness (2010, background): “Two consensus conferences have called on mental healthcare providers to take responsibility for the physical health of their patients (Fleischhacker et al., 2008; Marder et al., 2004).”
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011, background): “52 World Psychiatry 10:1 - February 2011 A number of reviews and studies have shown that people with severe mental illness (SMI), including schizophrenia, bipolar disorder, schizoaffective disorder and major depressive disorder, have an excess mortality, being two or three times as high as that in t”
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs (2012, background): “Antipsychotic medications associated with QTc prolongation (such as mesoridazine, pimozide, thioridazine, sertindole and ziprasidone) should not be prescribed to patients with known heart disease, a personal history of syncope, a family history of early SCD (”
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009, background): “Over recent years, both national and international groups have developed screening and monitoring guidelines [5,10,22, 31,34,42,48,90,115,133,137] but these are not being routinely implemented in the clinical care of patients [20,63,87,99], although they appear to be cost-effective [19].”